Rtz DL, Yen Revollo J, Paul J, He Y, et al. Cumulative genetic threat predicts platinum/taxane-induced neurotoxicity. Clin Cancer Res. 2013;19:57696. 4. Yap TA, 714272-27-2 Formula Carden CP, Kaye SB. Outside of chemotherapy: specific therapies in ovarian cancer. Nat Rev Cancer. 2009;nine:1671. five. Wu R, Hu TC, Rehemtulla A, Fearon ER, Cho KR. Preclinical testing of PI3K/ AKT/mTOR signaling inhibitors in the mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res. 2011;17:73592. 6. Mabuchi S, Kuroda H, Takahashi R, Sasano T. The PI3K/AKT/mTOR pathway as being a therapeutic focus on in ovarian cancer. Gynecol Oncol. 2015;137(1):173. 7. Lau MT, So WK, Leung Personal computer. Fibroblast development variable 2 induces E-cadherin down-regulation through PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian most cancers cells. PLoS 1. 2013;8:e59083. eight. Yang YI, Ahn JH, Lee KT, Shih Ie M, Choi JH. RSF1 can be a beneficial regulator of NFkappaB-induced gene expression expected for ovarian most cancers chemoresistance. Most cancers Res. 2014;seventy four:22589. 9. Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, et al. Period II trial in the mTOR inhibitor, temsirolimus and evaluation ofLiu et al. Journal of Ovarian Exploration (2015) eight:Site nine of10.11.12.13. fourteen. fifteen. sixteen.17. eighteen. 19.twenty.21.22.23. 24. twenty five.26. 27. 28.circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Team analyze. Gynecol Oncol. 2011;123:196. Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM. Inhibition of CRM1dependent nuclear export sensitizes malignant cells to cytotoxic and specific agents. Semin Most cancers Biol. 2014;27:623. Noske A, Weichert W, Niesporek S, Roske A, Buckendahl AC, Koch I, et al. Expression from the nuclear export protein chromosomal region maintenance/ exportin 1/Xpo1 is often a prognostic element in human ovarian most cancers. Most cancers. 2008;112:17333. Wang Y, Xiang J, Ji F, Deng Y, Tang C, Yang S, et al. Knockdown of CRM1 inhibits the nuclear export of p27(Kip1) phosphorylated at serine ten and plays a task from the pathogenesis of epithelial ovarian most cancers. Cancer Lett. 2014;343:sixty three. Mor A, White MA, Fontoura BM. Nuclear trafficking in wellness and sickness. Curr Opin Cell Biol. 2014;28:285. Fung HY, Chook YM. Atomic basis of CRM1-cargo recognition, release and inhibition. Semin Cancer Biol. 2014;27:521. Parikh K, Cang S, Sekhri A, Liu D. Selective inhibitors of nuclear export (SINE) novel course of 1083162-61-1 Epigenetics anti-cancer brokers. J Hematol Oncol. 2014;7:78. Liu X, Niu M, Xu X, Cai W, Zeng L, Zhou X, et al. CRM1 is really a immediate mobile target from the purely natural anti-cancer agent plumbagin. J Pharmacol Sci. 2014;124:4863. Newlands ES, Rustin GJ, 6-?Thioinosine supplier Brampton MH. Stage I trial of elactocin. Br J Most cancers. 1996;74:648. Gerecitano J. SINE (selective inhibitor of nuclear export) ranslational science inside of a new class of anti-cancer agents. J Hematol Oncol. 2014;7:67. Liu X, Cai W, Niu M, Chong Y, Liu H, Hu W, et al. Plumbagin induces expansion inhibition of human glioma cells by downregulating the expression and exercise of FOXM1. J Neurooncol. 2015;121:4697. Niu M, Solar Y, Liu X, Tang L, Qiu R. Tautomycetin induces apoptosis by inactivating Akt by way of a PP1-independent signaling pathway in human breast most cancers cells. J Pharmacol Sci. 2013;121:174. Sunshine Q, Carrasco YP, Hu Y, Guo X, Mirzaei H, Macmillan J, et al. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci U S A. 2013;110:1303. Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM.